Source comparison
Melanotan II Versus Related Melanocortin Compounds
Melanotan II is best understood in the context of its relatives, because vendors exploit the confusion among them and because the comparison clarifies what “approved” actually means. Four compounds share the melanocortin lineage but differ profoundly in select
This comparison does not assign a generated winner or score.
- Melanotan II is best understood in the context of its relatives, because vendors exploit the confusion among them and because the comparison clarifies what “approved” actually means. Four compounds share the melanocortin lineage but differ profoundly in selectivity, evidence, and legal standing.
- Endogenous alpha-MSH is the natural benchmark: a 13-amino-acid hormone that activates melanocortin receptors but is degraded within minutes, making it useless as a drug and the reason the Arizona chemists built stabilized analogs in the first place.16 Afamelanotide (Melanotan I, Scenesse) is the linear, more MC1R-focused analog that completed formal clinical development. On October 8, 2019, the FDA approved it, delivered as a 16 mg subcutaneous implant every two months, to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP), a rare inherited photodermatosis.11 In pivotal trials, patients receiving afamelanotide spent more total hours in direct sunlight on pain-free days than those on placebo, and the drug was granted first-in-class status; it had earlier been approved in Europe.11,12 The crucial points for a reader are that afamelanotide is a different molecule from Melanotan II, is approved only for a rare disease
- Bremelanotide (PT-141, Vyleesi) is the other approved relative, and its history is directly tied to Melanotan II. Because Melanotan II produced sexual arousal via central MC4R in the early tanning work, a metabolite-derived analog was developed specifically for that effect; the FDA approved bremelanotide in June 2019 as an on-demand subcutaneous injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women.13 It acts on MC4R in the hypothalamus, particularly the paraventricular nucleus, engaging downstream oxytocin circuitry, a fundamentally central mechanism unlike the vascular action of PDE5 inhibitors.19 Researchers who study these pathways often cross-reference the PT-141 dosage protocol because bremelanotide is the melanocortin agonist with the most structured human sexual-function data.
- alpha-MSH (natural)
- Broad, low stability
- Not a drug
- None (endogenous hormone)
- Afamelanotide (Melanotan I / Scenesse)
- MC1R-focused
- FDA-approved (2019)
- Photoprotection in EPP, implant only
- Bremelanotide (PT-141 / Vyleesi)
- MC4R-preferring
- HSDD in premenopausal women
- Melanotan II
- Non-selective MC1/3/4/5R
- Not FDA-approved
- None; research chemical only
- The comparison drives home the point that “melanocortin peptide” is not a guarantee of anything. Two members of the family cleared the FDA bar by demonstrating efficacy and characterizing safety in structured trials for specific medical indications, and both are delivered under controlled conditions. Melanotan II, the very compound most heavily marketed to consumers, is the one that never completed that path. Its non-selectivity, activating pigment, appetite, arousal, and autonomic pathways simultaneously, is precisely why it is a harder molecule to develop safely than its more focused cousins, and why it has instead ended up as an unregulated product rather than a licensed medicine. Readers comparing melanocortin agents can browse the broader peptide dosage index to see how these related molecules are catalogued side by side.